Cardinal Health CAH · NYSE
$257.44 -0.04% (-$0.11)
Summary
56 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 79% a year over the last 3 years.
- It has raised its dividend 15 years in a row and pays out only 28% of profit.
- The share price is below the Bulios Fair Price.
- It earns 13 USD a year on every 100 USD of invested capital.
What to watch
- Out of every 100 USD of revenue, only 0.7 USD is left as net profit.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 34.1 USD for 1 USD of yearly profit. Over the last five years it was 40.6 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 9.4% a year over 5 years. Over the last 3 years it grew by 7.4% a year. For the next fiscal year analysts expect revenue to grow by 4.5%. Earnings per share grew by 79% a year over the last 3 years.
Growth in detailDoes it make money?
PoorlyWhere 100 USD of revenue goes
- Cost of sales 96 USD
- Sales and administration 2.8 USD
- Taxes and other 0.4 USD
- Net profit 0.7 USD
Net profit, industry median (Medical - Distribution) 1.4 USD
Out of every 100 USD of revenue, 0.7 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.2 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 0.81%
- Paid out of profit
- 28%
- Raised in a row
- 15 years
You receive $2.05 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 18
- Hold 15
- Sell 0
Today's price within the analysts' price targets
The average target of $273.22 is 6.1% above today's price. 55% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2026By product
- Pharmaceutical Member 92%
- GMPD 5.0%
- Other Operating Segment 2.7%
By region
- UNITED STATES 99%
- Non-US 0.7%
Pharmaceutical Member brings in 92% of revenue. Other Operating Segment grew fastest, by 23% a year.
Segments in detail